近日，Dupixent获美国FDA批准，用于治疗中重度大疱性类天疱疮（BP）成人患者。这款由赛诺菲/再生元打造的“自免药王”成功再拓疆土，持续巩固其在自身免疫领域的霸主地位。自免市场竞争格局自免已成为全球仅次于肿瘤的第二大疾病领域，2022年全球市场 ...

今日，再生元（Regeneron ...

The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

再生元 (REGN.US)和赛诺菲 (SNY.US)联合开发的重磅疗法Dupixent (dupilumab)获美国FDA批准，用于治疗大疱性类天疱疮 (BP)成人患者。根据新闻稿，Dupixent是获美国FDA批准的首款BP疗法。

The Food and Drug Administration approved the drug for adult patients with bullous pemphigoid, which mainly affects the ...

Sanofi SNY and its partner, Regeneron REGN, announced that the FDA has approved their blockbuster medicine, Dupixent ...

Regeneron and Sanofi are committed to helping patients in the U.S. who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Sanofi and Regeneron are committed to helping patients in the US who are prescribed Dupixent gain access to the medicine and receive the support they may need with the DUPIXENT MyWay® program. For ...

Paris: Sanofi has received approval from the US Food and Drug Administration (FDA) for Dupixent (dupilumab) for the treatment ...